The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
Open accessAbstract
Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug’s pharmacokinetics related to the conventional formulation. Poly(lactide- co -glycolide) (PLGA) is a biocompatible/biodegradable polymer with variable physicochemical characteristics, and its application in human has been approved by the United States Food and Drug Administration. PLGA gives polymeric nanoparticles with unique drug delivery characteristics. The application of PLGA nanoparticles (NPs) as intravenous (IV) sustained-release delivery vehicles for docetaxel can favorably modify pharmacokinetics, biofate, and pharmacotherapy of the drug in cancer patients. Surface modification of PLGA NPs with poly(ethylene glycol) (PEG) can further enhance NPs’ long-circulating properties. Herein, an optimized fabrication approach has been used for the preparation of PLGA and PLGA–PEG NPs loaded with docetaxel for IV application. Both types of NP formulations demonstrated in vitro characteristics that were considered suitable for IV administration (with long-circulating sustained-release purposes). NP formulations were IV administered to an animal model, and docetaxel’s pharmacokinetic and biodistribution profiles were determined and compared between study groups. PLGA and PEGylated PLGA NPs were able to modify the pharmacokinetics and biodistribution of docetaxel. Accordingly, the mode of changes made to pharmacokinetics and biodistribution of docetaxel is attributed to the size and surface properties of NPs. NPs contributed to increased blood residence time of docetaxel fulfilling their role as long-circulating sustained-release drug delivery systems. Surface modification of NPs contributed to more pronounced docetaxel blood concentration, which confirms the role of PEG in conferring long-circulation properties to NPs. Keywords: poly(lactide-co-glycolide), poly(lactide-co-glycolide)–poly(ethylene glycol), polymeric nanoparticles, docetaxel, emulsification solvent evaporation, sustained release, pharmacokinetics, biodistribution
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres
Gref, R., Domb, A., Quellec, P., Blunk, T., Müller, R. H., Verbavatz, J. M., & Langer, R. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00026-4 · Cited by 820
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles
Cedervall, T., Lynch, I., Foy, M., Berggård, T., Donnelly, S. C., Cagney, G., Linse, S., & Dawson, K. A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700465 · Cited by 777
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles
Cedervall, T., Lynch, I., Foy, M., Berggård, T., Donnelly, S. C., Cagney, G., Linse, S., & Dawson, K. A. (2007) · Angewandte Chemie · doi:10.1002/ange.200700465 · Cited by 655
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
Sarin, H. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-14 · Cited by 562
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi, S. M., Hunter, A. C., & Andresen, T. L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134623 · Cited by 545
Kircher, M. F., Mahmood, U., King, R. S., Weissleder, R., & Josephson, L. (2003) · PubMed · Cited by 543
Yoo, J.-W., Chambers, E., & Mitragotri, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791920496 · Cited by 521
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18905 · Cited by 453
Clinical Pharmacokinetics of Docetaxel
Clarke, S. J., & Rivory, L. P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00002 · Cited by 446
PLA/PLGA nanoparticles for sustained release of docetaxel
Musumeci, T., Ventura, C. A., Giannone, I., Ruozi, B., Montenegro, L., Pignatello, R., & Puglisi, G. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.06.023 · Cited by 435
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Nanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption
Gessner, A., Waicz, R., Lieske, A., Paulke, B.-R., Mäder, K., & Müller, R. H. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00432-9 · Cited by 358
Pharmacokinetic Consequences of Pegylation
Hamidi, M., Azadi, A., & Rafiei, P. (2006) · Drug Delivery · doi:10.1080/10717540600814402 · Cited by 301
Self-citationRole of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Mosqueira, V. C. F., Legrand, P., Morgat, J.-L., Vert, M., Mysiakine, E., Gref, R., Devissaguet, J.-P., & Barratt, G. (2001) · Pharmaceutical Research · doi:10.1023/a:1012248721523 · Cited by 289
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
The effects of particle size, density and shape on margination of nanoparticles in microcirculation
Toy, R., Hayden, E., Shoup, C., Baskaran, H., & Karathanasis, E. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/11/115101 · Cited by 254
Rensen, P. C. N., Sliedregt, L. A. J. M., Ferns, M., Kieviet, E., van Rossenberg, S. M. W., van Leeuwen, S. H., van Berkel, T. J. C., & Biessen, E. A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101786200 · Cited by 231
Mode of action of docetaxel – a basis for combination with novel anticancer agents
Herbst, R. S., & Khuri, F. R. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00097-5 · Cited by 230
Nagayama, S., Ogawara, K.-I., Fukuoka, Y., Higaki, K., & Kimura, T. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.036 · Cited by 225
Avgoustakis, K. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00224-2 · Cited by 211
Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Wang, J., Sui, M., & Fan, W. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110827 · Cited by 205
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity
ZHANG, J., LIU, F., & HUANG, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.004 · Cited by 195
Chu, K. S., Hasan, W., Rawal, S., Walsh, M. D., Enlow, E. M., Luft, J. C., Bridges, A. S., Kuijer, J. L., Napier, M. E., Zamboni, W. C., et al. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.008 · Cited by 173
Patel, B., Gupta, N., & Ahsan, F. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.001 · Cited by 168
Clinical Pharmacokinetics of Docetaxel: Recent Developments
Baker, S. D., Sparreboom, A., & Verweij, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645030-00002 · Cited by 162
Sanna, V., Roggio, A. M., Posadino, A. M., Cossu, A., Marceddu, S., Mariani, A., Alzari, V., Uzzau, S., Pintus, G., & Sechi, M. (2011) · Nanoscale Research Letters · doi:10.1186/1556-276x-6-260 · Cited by 160
Cellular distribution of injected PLGA-nanoparticles in the liver
Park, J., Utsumi, T., Seo, Y.-E., Deng, Y., Satoh, A., Saltzman, W. M., & Iwakiri, Y. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.01.013 · Cited by 160
Taxanes: an overview of the pharmacokinetics and pharmacodynamics
Vaishampayan, U. N., Parchment, R. E., Jasti, B., & Hussain, M. (1999) · Urology · doi:10.1016/s0090-4295(99)00451-3 · Cited by 149
Preclinical pharmacokinetics of paclitaxel and docetaxel
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199801000-00001 · Cited by 145
Docetaxel Nanotechnology in Anticancer Therapy
Zhao, P., & Astruc, D. (2012) · ChemMedChem · doi:10.1002/cmdc.201200052 · Cited by 136
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins
Loos, W. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00222-4 · Cited by 109
Cho, C., Keum, C.-G., Noh, Y., & Shin, S. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s24547 · Cited by 107
A Pharmacokinetic Overview of Nanotechnology-Based Drug Delivery Systems: An ADME-Oriented Approach
Hamidi, M., Azadi, A., Rafiei, P., & Ashrafi, H. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013007419 · Cited by 99
Self-citationCytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells
Jin, C. S., Bai, L., Wu, H., Song, W., Guo, G., & Dou, K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9889-z · Cited by 95
Shedding Light on Tumors Using Nanoparticles
Rao, J. (2008) · ACS Nano · doi:10.1021/nn800669n · Cited by 91
Jain, S., Gollapalli, S., Agrawal, A. K., Kushwah, V., & Thanki, K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00281 · Cited by 91
Murugesan, S., Mishra, P., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802088598 · Cited by 75
Contact allergenic activity of Tween® 80 before and after air exposure
Bergh, M., Magnusson, K., Nilsson, J., & Karlberg, A. (1997) · Contact Dermatitis · doi:10.1111/j.1600-0536.1997.tb00368.x · Cited by 71
Anticancer drug delivery with nanoparticles.
(2006) · PubMed · Cited by 68
Zhang, H., Cui, W., Bei, J., & Wang, S. (2006) · Polymer Degradation and Stability · doi:10.1016/j.polymdegradstab.2006.03.004 · Cited by 62
Dinarvand, R., Koopaei, M. N., Amini, Rabbani, Ostad, S. N., & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23211 · Cited by 58
Esmaeili, F., Dinarvand, R., Ghahremani, M. H., Ostad, S. N., Esmaily, H., & Atyabi, F. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328331f934 · Cited by 49
Esmaeili, F., Atyabi, F., & Dinarvand, R. (2008) · DARU Journal of Pharmaceutical Sciences · Cited by 36
Gupta, M., Chashoo, G., Sharma, P. R., Saxena, A. K., Gupta, P. N., Agrawal, G. P., & Vyas, S. P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400404p · Cited by 36
Mechanical modulation of cardiac microtubules
White, E. (2011) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-011-0963-0 · Cited by 32
Zhang, Z., Yu, Tân, Zhuang, Song, Wang, Zhou, & Zhao (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s48214 · Cited by 30
Quantitation and Distribution of β-tubulin in Human Cardiac Myocytes
Aquila-Pastir, L. A., DiPaola, N. R., Matteo, R., Smedira, N. G., McCarthy, P. M., & Moravec, C. S. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2105 · Cited by 29
Rafiei, P., Michel, D. L., & Haddadi, A. (2015) · American Journal of Analytical Chemistry · doi:10.4236/ajac.2015.62015 · Cited by 14
Self-citationBiodegradable Nanoparticles and Their In Vivo Fate
Kumari, A., Singla, R., Guliani, A., & Yadav, S. K. (2016) · Springer eBooks · doi:10.1007/978-981-10-0818-4_2 · Cited by 10
Cited by
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
Advancements in nanoparticle-based treatment approaches for skin cancer therapy
Zeng, L., Gowda, B. H. J., Ahmed, M. G., Abourehab, M. A. S., Chen, Z.-S., Zhang, C., Li, J., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01708-4 · Cited by 365
Sharma, S., Sudhakara, P., Singh, J., Ilyas, R. A., Asyraf, M. R. M., & Razman, M. R. (2021) · Polymers · doi:10.3390/polym13162623 · Cited by 288
Stealth nanoparticles in oncology: Facing the PEG dilemma
Zalba, S., ten Hagen, T. L. M., Burgui, C., & Garrido, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.002 · Cited by 278
Metadata
- Authors
- Rafiei, P., & Haddadi, A.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-01
- Volume
- Volume 12
- Pages
- 935-947
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2582481970
- Cited by
- 284
- References
- 63
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.